Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.

Subjects

Subjects :

Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents therapeutic use
Bevacizumab
Breast Neoplasms drug therapy
Breast Neoplasms economics
Canada
Carcinoma, Ovarian Epithelial
Clinical Trials as Topic
Colorectal Neoplasms drug therapy
Colorectal Neoplasms economics
Cost-Benefit Analysis
Disease-Free Survival
European Union
Evidence-Based Medicine
Female
Humans
Lung Neoplasms drug therapy
Lung Neoplasms economics
Politics
Recurrence
Survival Analysis
Treatment Outcome
United Kingdom
United States
United States Food and Drug Administration
Vascular Endothelial Growth Factor A antagonists & inhibitors
Antibodies, Monoclonal, Humanized economics
Antineoplastic Agents economics
Drug Approval
Drug Costs
Neoplasms, Glandular and Epithelial drug therapy
Neoplasms, Glandular and Epithelial economics
Ovarian Neoplasms drug therapy
Ovarian Neoplasms economics

Details

Language :

English

ISSN :

1527-7755

Volume :

33

Issue :

14

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

25847922

Full Text :

https://doi.org/10.1200/JCO.2014.58.3690